Onconova Therapeutics Announces Dosing Of First Participant In Investigator-Sponsored Phase 2 Trial Of Rigosertib Plus Pembrolizumab In Metastatic Melanoma Patients Refractory To Immune Checkpoint Blockade
Portfolio Pulse from Happy Mohamed
Onconova Therapeutics has announced the dosing of the first participant in an investigator-sponsored Phase 2 trial of oral rigosertib plus pembrolizumab for metastatic melanoma patients who have progressed on prior PD-1/L1 inhibitor therapy. The trial aims to explore the potential of rigosertib to enhance the efficacy of immune checkpoint blockade in metastatic melanoma.
May 25, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Onconova Therapeutics has initiated a Phase 2 trial of rigosertib plus pembrolizumab for metastatic melanoma patients, potentially expanding the company's pipeline.
The initiation of the Phase 2 trial for rigosertib plus pembrolizumab in metastatic melanoma patients is a positive development for Onconova Therapeutics. If the trial is successful, it could expand the company's pipeline and potentially lead to increased revenues in the future. This news is directly related to the company and is important for investors, as it shows progress in the development of their products.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100